WO2025170074A1 - 双性イオン及び難溶性物質溶解剤 - Google Patents

双性イオン及び難溶性物質溶解剤

Info

Publication number
WO2025170074A1
WO2025170074A1 PCT/JP2025/004239 JP2025004239W WO2025170074A1 WO 2025170074 A1 WO2025170074 A1 WO 2025170074A1 JP 2025004239 W JP2025004239 W JP 2025004239W WO 2025170074 A1 WO2025170074 A1 WO 2025170074A1
Authority
WO
WIPO (PCT)
Prior art keywords
cation
carbon atoms
group
zwitterion
hydrocarbon group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
PCT/JP2025/004239
Other languages
English (en)
French (fr)
Japanese (ja)
Inventor
浩介 黒田
宏太 柴▲崎▼
健太 熊倉
雄太 斉藤
絢子 坂戸
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nippon Nyukazai Co Ltd
Japan Science and Technology Agency
Original Assignee
Nippon Nyukazai Co Ltd
Japan Science and Technology Agency
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nippon Nyukazai Co Ltd, Japan Science and Technology Agency filed Critical Nippon Nyukazai Co Ltd
Priority to JP2025575600A priority Critical patent/JP7836059B2/ja
Publication of WO2025170074A1 publication Critical patent/WO2025170074A1/ja
Pending legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C07D233/60Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms with hydrocarbon radicals, substituted by oxygen or sulfur atoms, attached to ring nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/04Preserving or maintaining viable microorganisms

Definitions

  • the present invention relates to zwitterions and agents for dissolving poorly soluble substances.
  • an object of the present invention is to provide a substance that can dissolve a wide range of poorly soluble substances and has low cytotoxicity.
  • [3] The zwitterion according to [1] or [2], wherein A is an imidazolium cation, an ammonium cation, a pyrazolium cation, a pyridinium cation, a pyrrolidinium cation, a morpholinium cation, or a piperidinium cation.
  • A is an imidazolium cation, an ammonium cation, a pyrazolium cation, a pyridinium cation, a pyrrolidinium cation, a morpholinium cation, or a piperidinium cation.
  • B is an anion selected from —COO ⁇ , —SO 3 ⁇ , and —OP ⁇ O(OH)O ⁇ .
  • zwitterion refers to an ion having a zwitterionic structure.
  • a zwitterion is a molecule having both a positive charge and a negative charge in one molecule, and is also called a zwitterion.
  • a poorly soluble substance refers to a substance that has low solubility in a solvent such as water.
  • a solubilizer for a poorly soluble substance refers to an agent that dissolves a poorly soluble substance.
  • poorly soluble and poorly soluble are treated as synonyms.
  • a cell cryopreservation agent is an agent that is added when cryopreserving various cells, and is an additive that protects cells during freezing and thawing.
  • One aspect of the present invention is a compound represented by general formula (1):
  • the zwitterion of the present invention has a cationic moiety represented by A and an anionic moiety represented by B.
  • the zwitterion of the present invention is characterized by the introduction of moderately hydrophilic ether chains ((OR 4 ) and (OR 3 )) into the cationic side chain of the zwitterion or into the spacer between the anion and the cation. This structure is believed to significantly improve the solubility of a wide range of poorly soluble substances compared to existing zwitterionic compounds.
  • R1 represents a substituted or unsubstituted linear or branched, saturated or unsaturated hydrocarbon group having 1 to 20 carbon atoms, a substituted or unsubstituted saturated or unsaturated non-aromatic cyclic hydrocarbon group having 3 to 20 carbon atoms, a substituted or unsubstituted aromatic hydrocarbon group having 6 to 30 carbon atoms, or a substituted or unsubstituted aromatic hydrocarbon-alkyl group having 7 to 31 carbon atoms.
  • substituted or unsubstituted means that a hydrogen atom of a group may or may not be substituted with another group.
  • the substituents that may be substituted are not particularly limited.
  • the number of substituents to be further substituted for one substituent is not particularly limited, and can be appropriately selected in consideration of the desired glycol ether structure. Note that, in the above, substitution with the same substituent is not performed. In other words, an alkyl group as a substituent is not substituted with another alkyl group.
  • n-octyl group 1-(n-propyl)butyl group, 1,1-dimethylpentyl group, 1,4-dimethylpentyl group, 1,1-diethylpropyl group, 1,3,3-trimethylbutyl group, 1-ethyl-2,2-dimethylpropyl group, n-octyl group, 2-methylhexan-2-yl group, 2,4-dimethylpentan-3-yl group, 1,1-dimethylpentan-1-yl group, 2,2-dimethylhexan-3-yl group, 2,3-dimethylhexan-2-yl group, 2,5-dimethylhexan-2-yl group, 2,5-dimethylhexan-3-yl group, 3,4-dimethylhexan-3-yl group, 3,5-dimethylhexan-3-yl group, 1-methylheptyl group, 2-methylheptyl group, 5- Methylheptyl group, 2-methylh
  • methyl, ethyl, isopropyl, n-butyl, isobutyl, n-hexyl, and 2-ethylhexyl are preferred, and from the viewpoint of toxicity, methyl, ethyl, isopropyl, n-butyl, and isobutyl are even more preferred.
  • linear or branched unsaturated hydrocarbon groups having 1 to 20 carbon atoms include vinyl, 1-propenyl, allyl, 1-butenyl, 3-butenyl, isoprenyl, pentenyl, hexenyl, heptenyl, octenyl, nonenyl, decenyl, undecenyl, dodecenyl, tridecenyl, tetradecenyl, pentadecenyl, hexadecenyl, and heptadecenyl groups.
  • octadecenyl groups for example, oleyl groups ((Z)-octadec-9-en-1-yl groups)), linoleoyl groups ((9Z,12Z)-octadeca-9,12-dienoyl groups), ⁇ -linolenoyl groups ((9Z,12Z,15Z)-octadeca-9,12,15-trienoyl groups), ⁇ -linolenoyl groups ((6Z,9Z,12Z)-octadeca-6,9,12-trienoyl groups), and the like.
  • octadecenyl groups for example, oleyl groups ((Z)-octadec-9-en-1-yl groups)
  • linoleoyl groups ((9Z,12Z)-octadeca-9,12-dienoyl groups)
  • saturated or unsaturated non-aromatic cyclic hydrocarbon group having 3 to 20 carbon atoms a saturated or unsaturated non-aromatic cyclic hydrocarbon group having 3 to 12 carbon atoms is preferred, a saturated or unsaturated non-aromatic cyclic hydrocarbon group having 3 to 8 carbon atoms is more preferred, and a saturated or unsaturated non-aromatic cyclic hydrocarbon group having 3 to 6 carbon atoms is even more preferred.
  • saturated non-aromatic cyclic hydrocarbon group having 3 to 20 carbon atoms include a cyclopropyl group, a cyclobutyl group, a cyclopentyl group, a cyclohexyl group, a cyclooctyl group, a norbornyl group, and an adamantyl group. From the viewpoint of production, a cyclopropyl group, a cyclobutyl group, a cyclopentyl group, and a cyclohexyl group are preferred.
  • unsaturated non-aromatic cyclic hydrocarbon groups having 3 to 20 carbon atoms include cyclopropenyl, cyclobutenyl, cyclopentenyl, 2,4-cyclopentadienyl, cyclohexenyl, 2,5-cyclohexadienyl, and cyclooctenyl.
  • aromatic hydrocarbon group having 6 to 30 carbon atoms an aromatic hydrocarbon group having 6 to 24 carbon atoms is preferred, an aromatic hydrocarbon group having 6 to 18 carbon atoms is more preferred, and an aromatic hydrocarbon group having 6 to 10 carbon atoms is even more preferred.
  • a phenyl group a biphenyl group, a 1-naphthyl group, a 2-naphthyl group, a 9-anthryl group, a 9-phenanthryl group, a 1-pyrenyl group, a 5-naphthacenyl group, a 1-indenyl group, a 2-azulenyl group, a 9-fluorenyl group, a terphenyl group, a quaterphenyl group, a mesityl group, a pentalenyl group, a binaphthalenyl group, a ternaphthalenyl group, a quaternaphthalenyl group, a heptalenyl group, a biphenylenyl group, an indacenyl group, a fluoranthenyl group, an acenaphthylenyl group, an aceanthryllenyl group, a
  • Aromatic hydrocarbon-alkyl groups having 7 to 31 carbon atoms are preferably aromatic hydrocarbon-alkyl groups having 7 to 25 carbon atoms, more preferably aromatic hydrocarbon-alkyl groups having 7 to 19 carbon atoms, and even more preferably aromatic hydrocarbon-alkyl groups having 7 to 16 carbon atoms. Examples include phenyl-C1-6 alkyl groups, naphthyl-C1-6 alkyl groups, and anthracenyl-C1-6 alkyl groups.
  • A is the cation portion of the zwitterion and represents a cation selected from imidazolium cation, phosphonium cation, ammonium cation, sulfonium cation, pyrazolium cation, pyridinium cation, pyrrolidinium cation, morpholinium cation, cyclopropenylium cation, and piperidinium cation.
  • R5 represents an alkyl group having 1 to 8 carbon atoms which may have a heteroatom, and examples of R5 include a methyl group and an ethyl group.
  • the zwitterion represented by general formula (1) can be produced, for example, according to the following reaction scheme:
  • R6 represents an alkyl group or an aromatic hydrocarbon group.
  • the alkyl group include linear or branched alkyl groups having 1 to 8 carbon atoms. Specifically, a methyl group, an ethyl group, or a tert-butyl group is more preferred.
  • the aromatic hydrocarbon group include a phenyl group, a halogenophenyl group, and a nitrophenyl group.
  • R7 represents an alkyl group, a halogenoalkyl group, or an aromatic hydrocarbon group.
  • the alkyl group include linear or branched alkyl groups having 1 to 8 carbon atoms. Specifically, methyl groups, ethyl groups, and the like are more preferred.
  • the halogenoalkyl group include fluoroalkyl groups. Specifically, examples include trifluoromethyl groups.
  • the aromatic hydrocarbon group include alkylphenyl groups. Specifically, examples include p-toluene groups.
  • This reaction is preferably carried out in the presence of a base, such as a tertiary amine, triethylamine, 4-dimethylaminopyridine, or an inorganic base, such as sodium hydroxide, potassium hydroxide, sodium bicarbonate, Na, or sodium hydride.
  • a base such as a tertiary amine, triethylamine, 4-dimethylaminopyridine, or an inorganic base, such as sodium hydroxide, potassium hydroxide, sodium bicarbonate, Na, or sodium hydride.
  • the reaction may be carried out in a solvent at a temperature of 0° C. to 100° C. for about 1 hour to 40 hours.
  • a general-purpose solvent such as a halogenated hydrocarbon such as dichloromethane, an aromatic hydrocarbon such as benzene or toluene, an ether, or acetonitrile can be used.
  • Step (2) is a step in which compound (4) is reacted with compound (5) to obtain compound (6).
  • This reaction is preferably carried out in the presence of a base.
  • the base include tertiary amines such as triethylamine and 4-dimethylaminopyridine, and inorganic bases such as sodium hydroxide, potassium hydroxide, sodium bicarbonate, Na, and sodium hydride.
  • the reaction may be carried out in a solvent at a temperature of 0° C. to 100° C. for about 1 hour to 40 hours.
  • Zwitterions represented by general formula (1) include those that are liquid at room temperature and those that are solid at 100°C, and are stable without decomposition up to temperatures above 100°C. Furthermore, they are low in toxicity and have the ability to dissolve poorly soluble substances, making them useful as solubilizers for poorly soluble substances and as cryopreservatives for cells. Solid zwitterions can also be made liquid by adding a small amount of water, for example, and can be used, like liquid zwitterions, as solubilizers for poorly soluble substances and as cryopreservatives for cells.
  • Another aspect of the present invention is a compound represented by general formula (1):
  • R 1 represents a substituted or unsubstituted linear or branched saturated or unsaturated hydrocarbon group having 1 to 20 carbon atoms, a substituted or unsubstituted saturated or unsaturated non-aromatic cyclic hydrocarbon group having 3 to 20 carbon atoms, a substituted or unsubstituted aromatic hydrocarbon group having 6 to 30 carbon atoms, or a substituted or unsubstituted aromatic hydrocarbon-alkyl group having 7 to 31 carbon atoms;
  • A represents a cation moiety of the zwitterion and is selected from the group consisting of imidazolium cation, phosphonium cation, ammonium cation, sulfonium cation, pyrazolium cation, pyridinium cation, pyrrolidinium cation, morpholinium cation, cyclopropenylium cation, and piperidinium cation; R2 represents an alkylene group having 1 to
  • the term "slightly soluble substance” refers to a substance that does not dissolve at all in water or dissolves only slightly, and has a solubility in water (25°C) of 1% by weight or less, preferably 0.5% by weight or less, and particularly preferably 0.1% by weight or less.
  • slightly soluble substances include substances that are active ingredients in pharmaceuticals, veterinary drugs, quasi-drugs, cosmetics, and agricultural chemicals (including candidate substances that may become active ingredients), food additives, biological substances, and plant-derived substances (excluding cellulose), and also includes low-molecular-weight substances, as well as oligomers and polymers such as oligopeptides, polypeptides, polysaccharides, DNA, and RNA.
  • Antineoplastic agents include methotrexate, taxol, doxorubicin hydrochloride, bleomycin hydrochloride, tamoxifen, cisplatin, carboplatin, cyclosporine, HER2 inhibitors, melphalan, dacarbazine, carmofur, enocitabine, etoposide, 5-fluorouracil, mitoxantrone, mesna, dimesna, aminoglutethimide, acrolein, cyclophosphamide, lomustine, carmustine, cyclophosphamide, busulfan, para-aminosalicylic acid, mercaptopurine, tegafur, azathioprine, vinblastine sulfate, mitomycin C, L-asparagine, ubenimex, paclitaxel, and dorsomorphin.
  • Antiviral agents include acyclovir, nevirapine, zidovudine, zanamivir, oseltamivir, and favipiravir.
  • isoflavones examples include ononin, daidzein, biochanin A, glycitein, daidzin, glycitin, and genistin.
  • Isoflavones may be either aglycones or glycosides.
  • Slightly soluble substances used in quasi-drugs or cosmetics include dl- ⁇ -tocopherol acetate, ⁇ -tocopherol (vitamin E), methyl cinnamate, ethyl cinnamate, hexyl laurate, trichlorocarbanilide, triazine, benzophenone, triazole, eugenol, isoeugenol, ethyl methylphenylglycidate, geranyl acetate, piperonal, cinnamyl acetate, decyl oleate, terpenyl acetate, anilides, cinnamide, sulfonated benzimidazole, carotene, piroctone olamine, minoxidil, phytosteside, tocopherol nicotinate, ethinyl estradiol, polyporsterone, and ecdysteroids.
  • poorly soluble fungicides include bromuconazole, carpropamid, diclofen, metconazole, hexaconazole, fentin, mancozeb, maneb, diclomedine, azoxystrobin, isoprothiolane, benalaxyl, benomyl, bitertanol, captafol, captan, carbendazim, quinomethionate, chlorothalonil, chlozolinate, cyprodinil, dichlofluanid, dicloran, diclocymet, diethofencarb, dimethomorph, diniconazole, dithianon, tiadinil, epoxiconazole, famoxadone, fenarimol, fenbuconazole, fenfuram, fenpiclonil, fluazinam, fludioxonil, fluoroquinol ...
  • Examples include imide, fluquinconazole, flusulfamide, flutolanil, folpet, hexachlorobenzene, imibenconazole, ipoconazole, iprodione, kresoxim-methyl, mepanipyrim, mepronil, metiram, nickel bis(dimethyldithiocarbamate), nuarimol, oxine copper, oxolinic acid, pencycuron, phthalide, procymidone, propineb, quintozene, sulfur, tebuconazole, tecloftalam, tecnazene, thifluzamide, thiophenate-methyl, thiram, tolclofos-methyl, triadimefon, tolylfluanid, triadimenol, triazoxide, triforine, triticonazole, vinclozolin, zineb, ziram, etc.
  • Slightly soluble herbicides include bromobutide, aclonifen, clomethoxyfen, lactofen, prometryn, propazine, azafenidine, thenylchlor, bifenox, sulfentrazone, pyraflufen-ethyl, flumiclorac-pentyl, flumioxazin, atrazine, indanofan, bensulfuron-methyl, benzofenap, bromofenoxime, chlorbromuron, chlorimuron-ethyl, chlornitrofen, chlorotoluron, chlorthal-dimethyl, clomeprop, dymron, desmedifam, dichlobenil, diflufenican, dimefuron, dinitramine, diuron, ethametsulfuron-methyl, triaziflam, fenoxaprop-ethyl, and furam.
  • Examples include propmethyl, flazasulfuron, flumetsulam, fluthiacet-methyl, flupoxam, fluridone, flurtamone, oxaziclomefone, isoproturon, isoxaben, isoxapyrifop, lenacil, linuron, mefenacet, methabenzthiazuron, metobenzuron, naproanilide, nevron, norflurazon, oryzalin, oxadiazon, oxyfluorfen, phenmedipham, prodiamine, propyzamide, pyrazolinate, pyrazosulfuron-ethyl, pyributicarb, quinclorac, quizalofop-ethyl, rimsulfuron, siduron, simazine, terbuthylazine, terbutryn, thiazopyr, tracoxydim, and trietazine.
  • polypeptides examples include collagen, casein, albumin, elastin, silk protein, etc.
  • R 1 represents a substituted or unsubstituted linear or branched saturated or unsaturated hydrocarbon group having 1 to 20 carbon atoms, a substituted or unsubstituted saturated or unsaturated non-aromatic cyclic hydrocarbon group having 3 to 20 carbon atoms, a substituted or unsubstituted aromatic hydrocarbon group having 6 to 30 carbon atoms, or a substituted or unsubstituted aromatic hydrocarbon-alkyl group having 7 to 31 carbon atoms;
  • A represents a cation moiety of the zwitterion and is selected from the group consisting of imidazolium cation, phosphonium cation, ammonium cation, sulfonium cation, pyrazolium cation, pyridinium cation, pyrrolidinium cation, morpholinium cation, cyclopropenylium cation, and piperidinium cation; R2 represents an alkylene group having 1 to
  • “Sarcoma” refers to cancers that develop in connective tissue cells derived from non-epithelial cells, such as bone, cartilage, fat, muscle, and blood, and includes soft tissue sarcoma and malignant bone tumors.
  • Sarcoma cells are cells derived from sarcoma.
  • Cell lines refer to cultured cells that have been maintained outside the body for a long period of time, have certain stable properties, and can be subcultured semi-permanently. Examples include PC12 cells (derived from rat adrenal medulla), CHO cells (derived from Chinese hamster ovary), HEK293 cells (derived from human fetal kidney), HL-60 cells (derived from human leukocytes), and HeLa cells (derived from human cervical cancer).
  • Transformed cells refer to cells whose genetic properties have been altered by introducing nucleic acid (e.g., DNA) from outside the cell. Transformation of animal cells, plant cells, and bacteria is performed using conventionally known methods. Furthermore, when culturing ES cells or iPS cells, feeder cells may be optionally included as supplementary cells used to create an environment necessary for cell proliferation and differentiation. Examples of feeder cells include mouse fibroblasts. These feeder cells can be pretreated with gamma irradiation or antibiotics to prevent proliferation.
  • nucleic acid e.g., DNA
  • the concentration of the zwitterion of the present invention in the cell cryopreservation agent is preferably 0.1 to 70% by weight, more preferably 1 to 50%, and even more preferably 3 to 30% based on the total weight of the cell cryopreservation agent.
  • the zwitterion of the present invention can prevent the formation of ice crystals and protect cells from physical destruction.
  • the contents of the ampoule are pipetted into a sterile tube. Pre-warmed medium with appropriate supplements is then slowly added. Viable cell density is measured using trypan blue. An appropriate amount of the cell suspension is transferred to a flask and seeded at the cell density recommended on the cell line data sheet.
  • diethylene glycol monoisobutyl ether p-toluenesulfonate 93.2 g of imidazole (manufactured by Fujifilm Wako Pure Chemical Industries, Ltd.), 932 g of tetrahydrofuran (manufactured by Fujifilm Wako Pure Chemical Industries, Ltd.), and 136.9 g of NaOH were mixed together. 433.2 g of diethylene glycol monoisobutyl ether p-toluenesulfonate was added, and the mixture was stirred at 60° C. for 7 hours.
  • (c) Thawing of cells and counting of viable cell count One ml of medium was added to a cryopreservation vial, followed by thawing and centrifugation to remove the supernatant. The cells obtained by centrifugation were then resuspended in medium and the viable cell count was counted.
  • the cell viability is the percentage (%) of the viable cell count after thawing to the sum of the viable cell count after thawing and the dead cell count after freezing, as shown in the following formula.
  • the cell recovery rate is calculated by dividing the viable cell count after thawing by the cell count before freezing, 1.0 x 10 6 (*10 6 ), and multiplying the result by 100.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
PCT/JP2025/004239 2024-02-09 2025-02-07 双性イオン及び難溶性物質溶解剤 Pending WO2025170074A1 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025575600A JP7836059B2 (ja) 2024-02-09 2025-02-07 双性イオン及び難溶性物質溶解剤

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2024-018970 2024-02-09
JP2024018970 2024-02-09

Publications (1)

Publication Number Publication Date
WO2025170074A1 true WO2025170074A1 (ja) 2025-08-14

Family

ID=96700181

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2025/004239 Pending WO2025170074A1 (ja) 2024-02-09 2025-02-07 双性イオン及び難溶性物質溶解剤

Country Status (2)

Country Link
JP (1) JP7836059B2 (https=)
WO (1) WO2025170074A1 (https=)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140255861A1 (en) * 2007-03-09 2014-09-11 The Regents Of The University Of Michigan Methods and compositions for growth of cells and embryonic tissue on a synthetic polymer matrix
US20190037832A1 (en) * 2016-04-08 2019-02-07 Tianjin University Cell Cryopreservation Protective Composition, Use Thereof, and Cell Cryopreservation Method
WO2020230721A1 (ja) * 2019-05-13 2020-11-19 国立研究開発法人科学技術振興機構 非プロトン性双性イオンを用いた未分化促進剤及び凍結保護剤

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140255861A1 (en) * 2007-03-09 2014-09-11 The Regents Of The University Of Michigan Methods and compositions for growth of cells and embryonic tissue on a synthetic polymer matrix
US20190037832A1 (en) * 2016-04-08 2019-02-07 Tianjin University Cell Cryopreservation Protective Composition, Use Thereof, and Cell Cryopreservation Method
WO2020230721A1 (ja) * 2019-05-13 2020-11-19 国立研究開発法人科学技術振興機構 非プロトン性双性イオンを用いた未分化促進剤及び凍結保護剤

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
????????????????, 01 July 2016 (Proceedings of the ANNUAL MEETING OF THE CELLULOSE SOCIETY OF JAPAN) *

Also Published As

Publication number Publication date
JPWO2025170074A1 (https=) 2025-08-14
JP7836059B2 (ja) 2026-03-26

Similar Documents

Publication Publication Date Title
US9023398B2 (en) Method for improving the aqueous solubility of poorly-soluble substances
JP2647556B2 (ja) 改良された生物学的活性を有するポリオキシプロピレン/ポリオキシエチレン共重合体類
KR101810148B1 (ko) 상처 치유를 위한 산화제 및 광활성화제의 조합
RU2395287C2 (ru) Раствор для профилактики спайкообразования и способ профилактики спайкообразования
US20050238693A1 (en) Process for the preparation and activation of susbstances and a means of producing same
JPH07509397A (ja) エマルジョン含有の,高度にフッ素化した塩素置換有機化合物,およびそれらを合成しそして使用する方法
US20090270310A1 (en) Process for the preparation of a nutrient formulation
JP7836059B2 (ja) 双性イオン及び難溶性物質溶解剤
JP7416495B2 (ja) 双性イオンを含む培地用添加剤
CN110742064A (zh) 一种改性脂质体及其组合物、制备方法与应用
Aravind et al. Sustained release of curcumin from fibrin matrix induces cancer cell death and immunomodulation
EP2211872A1 (en) Hyperbranched polyglycerol for improving heart function
WO2003022265A1 (en) Oily paclitaxel composition and formulation for chemoembolization and preparation method thereof
US20070148187A1 (en) Mastic gum composition for use as a dietary supplement in humans and animals
CN110227166A (zh) 一种肿瘤术中缓释化疗靶向制剂的药物载体及其制备方法
JP5909796B2 (ja) 難溶性物質の水溶解性改善方法
JP3766647B2 (ja) 多層リポソーム
AU2003229363B2 (en) Process for the preparation and activation of substances and a means of producing same
CN104784152B (zh) 一种甲砜霉素微囊及其制备方法与应用
RU2707558C1 (ru) Способ микрокапсуляции нуклеината натрия
AU2003239154B2 (en) Process for the preparation of a nutrient formulation
Tavartkiladze et al. AminoTriComplex: Preclinical and Clinical Evidence for a Multi-Component Phytochemical Formulation Targeting Oxidative Stress, Mitochondrial Function, and Cancer-Related Pathways
AU2003239154A1 (en) Process for the preparation of a nutrient formulation
BR102012032323A2 (pt) Nanopartículas oiliméricas contendo amitraz e/ou fluazuron, método de produção, formulação e usos
CZ15098U1 (cs) Stabilizační disperzní základ pro fotodynamickou diagnostiku a terapii

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 25752378

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2025575600

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2025575600

Country of ref document: JP